Find Talazoparib Tosylate manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

0

USDMF

0

CEP/COS

0

JDMF

0

EU WC

0

KDMF

0

NDC API

0

VMF

0

Listed Suppliers

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

Australia

0

South Africa

0

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

GLOBAL SALES INFORMATION

Regulatory FDF Prices

NA

MARKET PLACE

0

FDF

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

0

News #PharmaBuzz

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as:
Molecular Formula
C26H22F2N6O4S
Molecular Weight
552.6  g/mol
InChI Key
XBJSXSPNAZFBHC-QNBGGDODSA-N

Talazoparib Tosylate
1 2D Structure

Talazoparib Tosylate

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(11S,12R)-7-fluoro-11-(4-fluorophenyl)-12-(2-methyl-1,2,4-triazol-3-yl)-2,3,10-triazatricyclo[7.3.1.05,13]trideca-1(13),5,7,9-tetraen-4-one;4-methylbenzenesulfonic acid
2.1.2 InChI
InChI=1S/C19H14F2N6O.C7H8O3S/c1-27-18(22-8-23-27)15-16(9-2-4-10(20)5-3-9)24-13-7-11(21)6-12-14(13)17(15)25-26-19(12)28;1-6-2-4-7(5-3-6)11(8,9)10/h2-8,15-16,25H,1H3,(H,26,28);2-5H,1H3,(H,8,9,10)/t15-,16-;/m1./s1
2.1.3 InChI Key
XBJSXSPNAZFBHC-QNBGGDODSA-N
2.1.4 Canonical SMILES
CC1=CC=C(C=C1)S(=O)(=O)O.CN1C(=NC=N1)C2C(N=C3C=C(C=C4C3=C2NNC4=O)F)C5=CC=C(C=C5)F
2.1.5 Isomeric SMILES
CC1=CC=C(C=C1)S(=O)(=O)O.CN1C(=NC=N1)[C@@H]2[C@H](N=C3C=C(C=C4C3=C2NNC4=O)F)C5=CC=C(C=C5)F
2.2 Create Date
2012-05-28
3 Chemical and Physical Properties
Molecular Weight 552.6 g/mol
Molecular Formula C26H22F2N6O4S
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count10
Rotatable Bond Count3
Exact Mass552.13913070 g/mol
Monoisotopic Mass552.13913070 g/mol
Topological Polar Surface Area147 A^2
Heavy Atom Count39
Formal Charge0
Complexity1030
Isotope Atom Count0
Defined Atom Stereocenter Count2
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count2

Drugs in Development

read-more
read-more
  • Development Update

Details:

Talazoparib Tosylate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Breast Neoplasms.


Lead Product(s): Talazoparib Tosylate,Inapplicable

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Miscellaneous

Sponsor: Pfizer Inc

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable February 16, 2021

blank

01

Stanford University

Country
arrow
CPhI Japan
Not Confirmed

Stanford University

Country
arrow
CPhI Japan
Not Confirmed

Details : Talazoparib Tosylate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Breast Neoplasms.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

February 16, 2021

blank
  • Development Update

Details:

Trifluridine is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.


Lead Product(s): Trifluridine,Tipiracil HCl,Talazoparib Tosylate

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: Phase IProduct Type: Cytotoxic Drug

Sponsor: Pfizer Inc

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable August 12, 2020

blank

02

Roswell Park Cancer Institute

Country
arrow
CPhI Japan
Not Confirmed

Roswell Park Cancer Institute

Country
arrow
CPhI Japan
Not Confirmed

Details : Trifluridine is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

Product Name : Undisclosed

Product Type : Cytotoxic Drug

Upfront Cash : Inapplicable

August 12, 2020

blank
  • Development Update

Details:

Gemtuzumab Ozogamicin is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Leukemia, Myeloid, Acute.


Lead Product(s): Ozogamicin,Talazoparib,Talazoparib Tosylate

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: Phase IProduct Type: Antibody-drug Conjugate

Sponsor: Pfizer Inc

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable December 20, 2019

blank

03

Roswell Park Cancer Institute

Country
arrow
CPhI Japan
Not Confirmed

Roswell Park Cancer Institute

Country
arrow
CPhI Japan
Not Confirmed

Details : Gemtuzumab Ozogamicin is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Leukemia, Myeloid, Acute.

Product Name : Undisclosed

Product Type : Antibody-drug Conjugate

Upfront Cash : Inapplicable

December 20, 2019

blank

Details:

Talazoparib Tosylate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Breast Neoplasms.


Lead Product(s): Talazoparib Tosylate,Inapplicable

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Miscellaneous

Sponsor: Melinda Telli

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable March 27, 2015

blank

04

CPhI Japan
Not Confirmed
CPhI Japan
Not Confirmed

Details : Talazoparib Tosylate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Breast Neoplasms.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

March 27, 2015

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Europe

read-more
read-more

01

CPhI Japan
Not Confirmed
arrow
arrow
CPhI Japan
Not Confirmed

Talazoparibtosylat

Brand Name : Talzenna

Dosage Form : Capsule

Dosage Strength : 0.25mg

Packaging :

Approval Date :

Application Number :

Regulatory Info : Marketed

Registration Country : Norway

blank

02

CPhI Japan
Not Confirmed
arrow
arrow
CPhI Japan
Not Confirmed

Talazoparibtosylat

Brand Name : Talzenna

Dosage Form : Capsule

Dosage Strength : 1mg

Packaging :

Approval Date :

Application Number :

Regulatory Info : Marketed

Registration Country : Norway

blank

03

CPhI Japan
Not Confirmed
arrow
arrow
CPhI Japan
Not Confirmed

Talazoparib Tosylate

Brand Name : Talzenna

Dosage Form : Hard Capsule

Dosage Strength : 1MG

Packaging :

Approval Date : 11-09-2019

Application Number : 1191377005

Regulatory Info : Authorized

Registration Country : Spain

blank

04

CPhI Japan
Not Confirmed
arrow
arrow
CPhI Japan
Not Confirmed

Talazoparib Tosylate

Brand Name : Talzenna

Dosage Form : Hard Capsule

Dosage Strength : 0.1MG

Packaging :

Approval Date : 15-01-2024

Application Number : 191377007

Regulatory Info : Authorized

Registration Country : Spain

blank

05

CPhI Japan
Not Confirmed
arrow
arrow
CPhI Japan
Not Confirmed

Talazoparib Tosilate

Brand Name : Talzenna

Dosage Form : Hard Capsules

Dosage Strength : 0.1mg

Packaging :

Approval Date : 05-01-2024

Application Number : 28106916023

Regulatory Info : Prescription

Registration Country : Denmark

blank

06

CPhI Japan
Not Confirmed
arrow
arrow
CPhI Japan
Not Confirmed

Talazoparib Tosilate

Brand Name : Talzenna

Dosage Form : Hard Capsules

Dosage Strength : 0.25mg

Packaging :

Approval Date : 20-06-2019

Application Number : 28106121818

Regulatory Info : Prescription

Registration Country : Denmark

blank

07

CPhI Japan
Not Confirmed
arrow
arrow
CPhI Japan
Not Confirmed

Talazoparib Tosilate

Brand Name : Talzenna

Dosage Form : Hard Capsules

Dosage Strength :

Packaging :

Approval Date : 20-06-2019

Application Number : 28106121918

Regulatory Info : Prescription

Registration Country : Denmark

blank

08

CPhI Japan
Not Confirmed
arrow
arrow
CPhI Japan
Not Confirmed

Talazoparib Tosylate

Brand Name : Talzenna

Dosage Form : Capsule

Dosage Strength : 0.25mg

Packaging :

Approval Date : 20-06-2019

Application Number : 2.02E+13

Regulatory Info : Approved

Registration Country : Sweden

blank

09

CPhI Japan
Not Confirmed
arrow
arrow
CPhI Japan
Not Confirmed

Talazoparib Tosylate

Brand Name : Talzenna

Dosage Form : Capsule

Dosage Strength :

Packaging :

Approval Date : 20-06-2019

Application Number : 2.02E+13

Regulatory Info : Approved

Registration Country : Sweden

blank

10

CPhI Japan
Not Confirmed
arrow
arrow
CPhI Japan
Not Confirmed

Talazoparib Tosylate

Brand Name : Talzenna

Dosage Form : Capsule

Dosage Strength : 0.35mg

Packaging :

Approval Date : 20-06-2025

Application Number : 2.02E+13

Regulatory Info : Approved

Registration Country : Sweden

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Canada

read-more
read-more

01

CPhI Japan
Not Confirmed
arrow
arrow
CPhI Japan
Not Confirmed

TALAZOPARIB (TALAZOPARIB TOSYLATE)

Brand Name : TALZENNA

Dosage Form : CAPSULE

Dosage Strength : 0.25MG

Packaging :

Approval Date :

Application Number : 2492032

Regulatory Info : PRESCRIPTION

Registration Country : Canada

blank

02

CPhI Japan
Not Confirmed
arrow
arrow
CPhI Japan
Not Confirmed

TALAZOPARIB (TALAZOPARIB TOSYLATE)

Brand Name : TALZENNA

Dosage Form : CAPSULE

Dosage Strength : 0.1MG

Packaging :

Approval Date :

Application Number : 2555050

Regulatory Info : PRESCRIPTION

Registration Country : Canada

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Global Sales Information

Do you need Business Intel? Ask us

US Medicaid Prescriptions

read-more
read-more

01

arrow
CPhI Japan
Not Confirmed
arrow
CPhI Japan
Not Confirmed

Company : Pfizer US Pharm

Talazoparib Tosylate

Drug Cost (USD) : 14,816,664

Year : 2023

Prescribers : 234

Prescriptions : 878

blank

02

arrow
CPhI Japan
Not Confirmed
arrow
CPhI Japan
Not Confirmed

Company : Pfizer US Pharm

Talazoparib Tosylate

Drug Cost (USD) : 6,401,237

Year : 2022

Prescribers : 81

Prescriptions : 430

blank

03

arrow
CPhI Japan
Not Confirmed
arrow
CPhI Japan
Not Confirmed

Company : Pfizer US Pharm

Talazoparib Tosylate

Drug Cost (USD) : 7,758,691

Year : 2021

Prescribers : 106

Prescriptions : 553

blank

04

arrow
CPhI Japan
Not Confirmed
arrow
CPhI Japan
Not Confirmed

Company : Pfizer US Pharm

Talazoparib Tosylate

Drug Cost (USD) : 8,270,787

Year : 2020

Prescribers : 128

Prescriptions : 558

blank

05

arrow
CPhI Japan
Not Confirmed
arrow
CPhI Japan
Not Confirmed

Company : Pfizer US Pharm

Talazoparib Tosylate

Drug Cost (USD) : 5,490,082

Year : 2019

Prescribers : 103

Prescriptions : 387

blank

06

arrow
CPhI Japan
Not Confirmed
arrow
CPhI Japan
Not Confirmed

Company : Pfizer US Pharm

Talazoparib Tosylate

Drug Cost (USD) : 162,688

Year : 2018

Prescribers :

Prescriptions : 11

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Annual Reports

read-more
read-more

01

Brand Name : Talzenna

Talazoparib Tosylate

arrow
CPhI Japan
Not Confirmed

Brand Name : Talzenna

U.S.A
arrow
CPhI Japan
Not Confirmed

Talazoparib Tosylate

Main Therapeutic Indication : Oncology

Currency : USD

2024 Revenue in Millions : 117

2023 Revenue in Millions : 64

Growth (%) : 83

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

US Patents

read-more
read-more

01

arrow
CPhI Japan
Not Confirmed

PFIZER

U.S.A
arrow
CPhI Japan
Not Confirmed

TALAZOPARIB TOSYLATE

US Patent Number : 10780088

Drug Substance Claim :

Drug Product Claim :

Application Number : 217439

Patent Use Code : U-3651

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2029-07-27

blank

02

arrow
CPhI Japan
Not Confirmed

PFIZER

U.S.A
arrow
CPhI Japan
Not Confirmed

TALAZOPARIB TOSYLATE

US Patent Number : 8420650

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 211651

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2029-07-27

blank

03

arrow
CPhI Japan
Not Confirmed

PFIZER

U.S.A
arrow
CPhI Japan
Not Confirmed

TALAZOPARIB TOSYLATE

US Patent Number : 9820985

Drug Substance Claim :

Drug Product Claim :

Application Number : 211651

Patent Use Code : U-2437

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2029-07-27

blank

04

arrow
CPhI Japan
Not Confirmed

PFIZER

U.S.A
arrow
CPhI Japan
Not Confirmed

TALAZOPARIB TOSYLATE

US Patent Number : 8012976

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 211651

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2029-07-27

blank

05

arrow
CPhI Japan
Not Confirmed

PFIZER

U.S.A
arrow
CPhI Japan
Not Confirmed

TALAZOPARIB TOSYLATE

US Patent Number : 9820985

Drug Substance Claim :

Drug Product Claim :

Application Number : 211651

Patent Use Code : U-2437

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2029-07-27

blank

06

arrow
CPhI Japan
Not Confirmed

PFIZER

U.S.A
arrow
CPhI Japan
Not Confirmed

TALAZOPARIB TOSYLATE

US Patent Number : 8420650

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 217439

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2029-07-27

blank

07

arrow
CPhI Japan
Not Confirmed

PFIZER

U.S.A
arrow
CPhI Japan
Not Confirmed

TALAZOPARIB TOSYLATE

US Patent Number : 8012976

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 211651

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2029-07-27

blank

08

arrow
CPhI Japan
Not Confirmed

PFIZER

U.S.A
arrow
CPhI Japan
Not Confirmed

TALAZOPARIB TOSYLATE

US Patent Number : 8012976

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 217439

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2029-07-27

blank

09

arrow
CPhI Japan
Not Confirmed

PFIZER

U.S.A
arrow
CPhI Japan
Not Confirmed

TALAZOPARIB TOSYLATE

US Patent Number : 10189837

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 211651

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2031-10-20

blank

10

arrow
CPhI Japan
Not Confirmed

PFIZER

U.S.A
arrow
CPhI Japan
Not Confirmed

TALAZOPARIB TOSYLATE

US Patent Number : 9820985

Drug Substance Claim :

Drug Product Claim :

Application Number : 217439

Patent Use Code : U-2437

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2029-07-27

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

US Exclusivities

read-more
read-more

01

arrow
CPhI Japan
Not Confirmed

PFIZER

U.S.A
arrow
CPhI Japan
Not Confirmed

TALAZOPARIB TOSYLATE

Exclusivity Code : I-920

Exclusivity Expiration Date : 2026-06-20

Application Number : 211651

Product Number : 1

Exclusivity Details :

blank

02

arrow
CPhI Japan
Not Confirmed

PFIZER

U.S.A
arrow
CPhI Japan
Not Confirmed

TALAZOPARIB TOSYLATE

Exclusivity Code : I-920

Exclusivity Expiration Date : 2026-06-20

Application Number : 211651

Product Number : 3

Exclusivity Details :

blank

03

arrow
CPhI Japan
Not Confirmed

PFIZER

U.S.A
arrow
CPhI Japan
Not Confirmed

TALAZOPARIB TOSYLATE

Exclusivity Code : I-920

Exclusivity Expiration Date : 2026-06-20

Application Number : 211651

Product Number : 5

Exclusivity Details :

blank

04

arrow
CPhI Japan
Not Confirmed

PFIZER

U.S.A
arrow
CPhI Japan
Not Confirmed

TALAZOPARIB TOSYLATE

Exclusivity Code : I-920

Exclusivity Expiration Date : 2026-06-20

Application Number : 217439

Product Number : 1

Exclusivity Details :

blank

05

arrow
CPhI Japan
Not Confirmed

PFIZER

U.S.A
arrow
CPhI Japan
Not Confirmed

TALAZOPARIB TOSYLATE

Exclusivity Code : I-920

Exclusivity Expiration Date : 2026-06-20

Application Number : 217439

Product Number : 2

Exclusivity Details :

blank

06

arrow
CPhI Japan
Not Confirmed

PFIZER

U.S.A
arrow
CPhI Japan
Not Confirmed

TALAZOPARIB TOSYLATE

Exclusivity Code : I-920

Exclusivity Expiration Date : 2026-06-20

Application Number : 217439

Product Number : 4

Exclusivity Details :

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Health Canada Patents

read-more
read-more

01

arrow
CPhI Japan
Not Confirmed
arrow
CPhI Japan
Not Confirmed

TALAZOPARIB TOSYLATE

Brand Name : TALZENNA

Patent Number : 2732797

Filing Date : 2009-07-27

Strength per Unit : 0.35 mg

Dosage Form : CAPSULE

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2029-07-27

Date Granted : 2017-01-03

blank

02

arrow
CPhI Japan
Not Confirmed
arrow
CPhI Japan
Not Confirmed

TALAZOPARIB TOSYLATE

Brand Name : TALZENNA

Patent Number : 2814581

Filing Date : 2011-10-20

Strength per Unit : 0.35 mg

Dosage Form : CAPSULE

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 1931-10-20

Date Granted : 2019-02-12

blank

03

arrow
CPhI Japan
Not Confirmed
arrow
CPhI Japan
Not Confirmed

TALAZOPARIB TOSYLATE

Brand Name : TALZENNA

Patent Number : 2732797

Filing Date : 2009-07-27

Strength per Unit : 0.5 mg

Dosage Form : CAPSULE

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2029-07-27

Date Granted : 2017-01-03

blank

04

arrow
CPhI Japan
Not Confirmed
arrow
CPhI Japan
Not Confirmed

TALAZOPARIB TOSYLATE

Brand Name : TALZENNA

Patent Number : 2814581

Filing Date : 2011-10-20

Strength per Unit : 0.5 mg

Dosage Form : CAPSULE

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 1931-10-20

Date Granted : 2019-02-12

blank

05

arrow
CPhI Japan
Not Confirmed
arrow
CPhI Japan
Not Confirmed

TALAZOPARIB TOSYLATE

Brand Name : TALZENNA

Patent Number : 2732797

Filing Date : 2009-07-27

Strength per Unit : 0.1 mg

Dosage Form : CAPSULE

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2029-07-27

Date Granted : 2017-01-03

blank

06

arrow
CPhI Japan
Not Confirmed
arrow
CPhI Japan
Not Confirmed

TALAZOPARIB TOSYLATE

Brand Name : TALZENNA

Patent Number : 2814581

Filing Date : 2011-10-20

Strength per Unit : 0.1 mg

Dosage Form : CAPSULE

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 1931-10-20

Date Granted : 2019-02-12

blank

07

Pfizer Canada ULC

arrow
CPhI Japan
Not Confirmed

Pfizer Canada ULC

Country
arrow
CPhI Japan
Not Confirmed

TALAZOPARIB TOSYLATE

Brand Name : TALZENNA

Patent Number : 2814581

Filing Date : 2011-10-20

Strength per Unit : 0.25 mg

Dosage Form : CAPSULE

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2031-10-20

Date Granted : 2019-02-12

blank

08

Pfizer Canada ULC

arrow
CPhI Japan
Not Confirmed

Pfizer Canada ULC

Country
arrow
CPhI Japan
Not Confirmed

TALAZOPARIB TOSYLATE

Brand Name : TALZENNA

Patent Number : 2732797

Filing Date : 2009-07-27

Strength per Unit : 0.25 mg

Dosage Form : CAPSULE

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2029-07-27

Date Granted : 2017-01-03

blank

09

Pfizer Canada ULC

arrow
CPhI Japan
Not Confirmed

Pfizer Canada ULC

Country
arrow
CPhI Japan
Not Confirmed

TALAZOPARIB TOSYLATE

Brand Name : TALZENNA

Patent Number : 2814581

Filing Date : 2011-10-20

Strength per Unit : 1 mg

Dosage Form : CAPSULE

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2031-10-20

Date Granted : 2019-02-12

blank

10

Pfizer Canada ULC

arrow
CPhI Japan
Not Confirmed

Pfizer Canada ULC

Country
arrow
CPhI Japan
Not Confirmed

TALAZOPARIB TOSYLATE

Brand Name : TALZENNA

Patent Number : 2732797

Filing Date : 2009-07-27

Strength per Unit : 1 mg

Dosage Form : CAPSULE

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2029-07-27

Date Granted : 2017-01-03

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Looking for / Talazoparib Tosylate API manufacturers, exporters & distributors?

Talazoparib Tosylate manufacturers, exporters & distributors 1

32

PharmaCompass offers a list of Talazoparib Tosylate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Talazoparib Tosylate manufacturer or Talazoparib Tosylate supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Talazoparib Tosylate manufacturer or Talazoparib Tosylate supplier.

API | Excipient name

Talazoparib Tosylate

Talazoparib Tosylate Manufacturers

A Talazoparib Tosylate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Talazoparib Tosylate, including repackagers and relabelers. The FDA regulates Talazoparib Tosylate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Talazoparib Tosylate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

Talazoparib Tosylate Suppliers

A Talazoparib Tosylate supplier is an individual or a company that provides Talazoparib Tosylate active pharmaceutical ingredient (API) or Talazoparib Tosylate finished formulations upon request. The Talazoparib Tosylate suppliers may include Talazoparib Tosylate API manufacturers, exporters, distributors and traders.

Talazoparib Tosylate GMP

Talazoparib Tosylate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Talazoparib Tosylate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Talazoparib Tosylate GMP manufacturer or Talazoparib Tosylate GMP API supplier for your needs.

Talazoparib Tosylate CoA

A Talazoparib Tosylate CoA (Certificate of Analysis) is a formal document that attests to Talazoparib Tosylate's compliance with Talazoparib Tosylate specifications and serves as a tool for batch-level quality control.

Talazoparib Tosylate CoA mostly includes findings from lab analyses of a specific batch. For each Talazoparib Tosylate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Talazoparib Tosylate may be tested according to a variety of international standards, such as European Pharmacopoeia (Talazoparib Tosylate EP), Talazoparib Tosylate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Talazoparib Tosylate USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty